
China Approves Lilly's Orforglipron Pill for Weight Management, the First Oral GLP-1 Cleared There for That Use
Shownotes
China's National Medical Products Administration has approved Eli Lilly's once-daily oral GLP-1 pill orforglipron, sold as Foundayo in the US and UK and as Muyouda in China, for long-term weight management, with the approval announced on November 12, 2026. It is the first oral GLP-1 approved for weight management in China, where only injectable GLP-1s had been approved for that use. The approval covers adults with a starting BMI of 30 or more, or 27 to under 30 with at least one weight-related condition such as high blood pressure, abnormal blood lipids, high blood sugar, obstructive sleep apnea or cardiovascular disease, alongside a reduced-calorie diet and more physical activity. A separate application for type 2 diabetes is still under review in China. Lilly has not disclosed a price or launch date and says it will supply the drug through authorized healthcare and pharmaceutical institutions. In the Lilly-funded ATTAIN-1 Phase 3 trial of 3,127 adults with obesity and without diabetes, published in the New England Journal of Medicine, average weight change at 72 weeks was -7.5%, -8.4% and -11.2% in the three orforglipron groups versus -2.1% with placebo; gastrointestinal side effects were the most common and mostly mild to moderate, and 5.3% to 10.3% stopped treatment because of adverse events versus 2.7% on placebo.
Sources
- China National Medical Products Administration approval notice (Nov 12, 2026), orforglipron calcium tablets, reprinted by China Pharmaceutical News (Chinese): cnpharm.com
- Lilly China press release (Nov 12, 2026), Muyouda (orforglipron) approved (Chinese): lilly.com.cn
- New England Journal of Medicine, Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1), abstract on PubMed: pubmed.ncbi.nlm.nih.gov
- Reuters via U.S. News (Nov 12, 2026), Eli Lilly Becomes First Drugmaker to Have a GLP-1 Weight-Loss Pill Approved in China: money.usnews.com
- Fierce Pharma regulatory tracker (Nov 12, 2026), Lilly beats Novo to land China's 1st oral GLP-1 weight loss nod: fiercepharma.com
Cover: original code-generated illustration (no photo).
This episode is for information only and is not medical advice. Always talk to your doctor before starting, stopping, or changing any medication.
Visit glp1newspaper.com for today's stories and free email alerts.
Alle Folgen von GLP-1 Newspaper: Daily Ozempic, Zepbound & Weight-Loss Drug News